SAT0362 Mycophenolate Mofetil versus Methotrexate in The Management of Large Vessel Giant Cell Arteritis

Dospinescu, Paula; Karabayas, Maira; Kidder, Dana; Fluck, Nick; Erwig, Lars P.; Mason, Justin C.; Basu, Neil

doi:10.1136/annrheumdis-2016-eular.4330

Cited by 4 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An initial case series ( n = 3) reported significant reduction in prednisolone dose in all three patients with newly diagnosed GCA treated with mycophenolate . A further retrospective study reported a similar steroid‐sparing effect for mycophenolate ( n = 11) compared to methotrexate ( n = 9) in a group of GCA patients with angiographically proven large‐vessel vasculitis …”

Section: Advances In Therapymentioning

confidence: 93%

See 1 more Smart Citation

Giant cell arteritis: beyond temporal artery biopsy and steroids

Ninan

Lester

Hill

2017

Internal Medicine Journal

View full text Add to dashboard Cite

Giant cell arteritis is the most common primary vasculitis of the elderly. The acute complications of untreated giant cell arteritis, such as vision loss or occasionally stroke, can be devastating. The diagnosis is, however, not altogether straightforward due to variable sensitivities of the temporal artery biopsy as a reference diagnostic test. In this review, we discuss the increasing role of imaging in the diagnosis of giant cell arteritis. Glucocorticoid treatment is the backbone of therapy, but it is associated with significant adverse effects. A less toxic alternative is required. Conventional and novel immunosuppressive agents have only demonstrated modest effects in a subgroup of steroid refractory Giant cell arteritis due to the different arms of the immune system at play. However, recently a study of interleukin-6 blockade demonstrated benefits of giant cell arteritis. The current status of these immunosuppressive agents and novel therapies are also discussed in this review.

show abstract

Section: Advances In Therapymentioning

confidence: 93%

“…64 A further retrospective study reported a similar steroid-sparing effect for mycophenolate (n = 11) compared to methotrexate (n = 9) in a group of GCA patients with angiographically proven large-vessel vasculitis. 65 Biological agents…”

Section: Leflunomidementioning

confidence: 99%

Giant cell arteritis: beyond temporal artery biopsy and steroids

Ninan

Lester

Hill

2017

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

“…However, the evidence supporting their use is largely limited to case series. [29][30][31][32][33][34][35] One small nonrandomized double-blind study of azathioprine in patients with either PMR or GCA showed a significant reduction in mean steroid dose over 52 weeks. 36 An RCT of hydroxychloroquine published in abstract form showed no evidence of efficacy.…”

Section: Synthetic Immunosuppressantsmentioning

confidence: 99%

Current advances in the treatment of giant cell arteritis: the role of biologics

Low

Conway

2019

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Giant cell arteritis (GCA) is the most common form of systemic vasculitis. It is a potentially severe disease with 25% of patients suffering vision loss or stroke. Our treatment paradigm is based on glucocorticoids. Glucocorticoids are required in high doses for prolonged periods and subsequently are associated with a significant amount of treatment-related morbidity. Alternative treatment options are urgently needed to minimize these glucocorticoid adverse events. Many other agents, such as methotrexate and tumour necrosis factor alpha inhibitors have been used in GCA, with limited or no evidence of benefit. Our emerging understanding of the pathogenic processes involved in GCA has led to an increased interest in the use of biologic agents to treat the disease. Two randomized controlled trials have recently reported dramatic effects of the use of the interleukin-6 targeted biologic tocilizumab in GCA, with significant increases in remission rates and decreases in glucocorticoid burden. While encouraging, longer-term and additional outcomes are awaited to clarify the exact positioning of tocilizumab in the treatment approach. Emerging data for other biologic agents, particularly abatacept and ustekinumab, are also encouraging but less well advanced. We are at the dawn of a new era in GCA treatment, but uncertainties and opportunities abound.

show abstract

Diagnosis and management of giant cell arteritis: an Asia‐Pacific perspective

2018

View full text Add to dashboard Cite

Giant cell arteritis is the commonest primary vasculitis of the elderly. However, the prevalence does vary widely between populations with highest incidence amongst Northern Europeans and lowest amongst East Asians. Preliminary studies suggest that clinical manifestations may differ between different populations. Newer diagnostic approaches including ultrasound, MR angiography and PET imaging are under review. While there have been recent advances in the diagnosis of GCA particularly with regard to imaging, there is an urgent need for improvements in methods of diagnosis, treatment and requirement for screening. Glucocorticoid treatment remain the backbone of therapy. However, glucocorticoid therapy is associated with significant adverse effects. Conventional and novel immunosuppressive agents have only demonstrated modest effects in a subgroup of steroid refractory GCA due to the different arms of the immune system at play. However, recently a study of IL-6 blockade demonstrated benefit in GCA. Newer approaches such as fast-track pathways can also result in improvements in consequences of GCA including blindness.

show abstract

SAT0362 Mycophenolate Mofetil versus Methotrexate in The Management of Large Vessel Giant Cell Arteritis

Cited by 4 publications

References 2 publications

Giant cell arteritis: beyond temporal artery biopsy and steroids

Giant cell arteritis: beyond temporal artery biopsy and steroids

Current advances in the treatment of giant cell arteritis: the role of biologics

Diagnosis and management of giant cell arteritis: an Asia‐Pacific perspective

Contact Info

Product

Resources

About